A commonly combined pair: CJC-1295, a long-acting GHRH analog, plus Ipamorelin, a selective GH secretagogue, run together so a GHRH analog and a GHRP act at once.
Reviewed for accuracy · Last reviewed July 7, 2026CJC-1295 and Ipamorelin are often combined because they act on growth-hormone release through two different mechanisms. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH), while Ipamorelin is a selective GH secretagogue that works through the ghrelin receptor (a GHRP). Pairing a GHRH analog with a GHRP is the rationale behind running them together, so a signal to release growth hormone comes from two directions at once.
The human evidence behind the stack is limited. CJC-1295's published human data comes mainly from small early-phase pharmacokinetic studies, and Ipamorelin's characterization is largely preclinical, with its main human program (a postoperative-ileus trial) not meeting its primary endpoint. Neither is FDA-approved, so any dosing here reflects community practice rather than an established regimen.
There is no established human dose. Community protocols commonly pair roughly 100 mcg of CJC-1295 with 200 – 300 mcg of Ipamorelin per dose, injected subcutaneously, often before bed. Neither peptide is FDA-approved.
Read the full CJC-1295 / Ipamorelin dosage guide →Human safety data is limited. Reported effects are mostly local or related to fluid shifts, such as injection-site irritation, water retention, and flushing. In its Phase 2 ileus trial, Ipamorelin was acceptably tolerated but did not meet the primary endpoint.
Read the full CJC-1295 / Ipamorelin side effects guide →Keep unmixed vials refrigerated and away from light. Once reconstituted, most research reports store each peptide refrigerated for roughly 4 weeks. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.